P2.08-05 IMRPrinter: A Phase 1/1b Trial of IMU-201 (Pd1-Vaxx) As Monotherapy or in Combination with Atezolizumab +/- Chemotherapy in NSCLC

Immune checkpoint inhibitors (ICI) are a part of standard of care treatment alone or in combination with chemotherapy in first-line advanced NSCLC. Only a subset of patients benefit from this treatment while others develop primary or acquired resistance due to lack of T-cell response, exhaustion, or other mechanisms (Yost, 2019). Resistance may be overcome by combining PD-1 + PD-L1 blockade to increase tumor-specific T-cells and generate memory T-cells (Burrack, 2019). IMU-201 is a B-cell peptide vaccine which stimulates polyclonal antibodies against PD-1 leading to active immunization and induction of memory B- and T-cells.